Dutch biotech starts liq­ui­da­tion af­ter end­ing PhI­II in GVHD

A 13-year-old Dutch biotech is go­ing through a liq­ui­da­tion process af­ter an un­ex­pect­ed end to its Phase III tri­al test­ing whether its com­bi­na­tion of two mon­o­clon­al an­ti­bod­ies was su­pe­ri­or to In­cyte’s Jakafi.

Xenikos had hoped to prove its in­ves­ti­ga­tion­al ther­a­py, named T-Guard, was bet­ter than Jakafi at gar­ner­ing a com­plete re­sponse in pa­tients ex­pe­ri­enc­ing life-threat­en­ing com­pli­ca­tions in which new cells from a hematopoi­et­ic stem cell trans­plant be­gin to fight the body. Jakafi was ap­proved for the in­di­ca­tion, steroid-re­frac­to­ry acute graft-ver­sus-host dis­ease, in May 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER